The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oncology precision medicine for hepatobiliary and pancreatic cancer: Insights and updates upon an institutional review.
 
Geoffrey Bellini
Travel, Accommodations, Expenses - Edwards Lifesciences; Edwards Lifesciences; Edwards Lifesciences; Edwards Lifesciences
 
Nicholas Sich
No Relationships to Disclose
 
Jennifer Jo Godden
No Relationships to Disclose
 
James L. Weese
Consulting or Advisory Role - Via Oncology; Via Oncology; Via Oncology; Via Oncology
Travel, Accommodations, Expenses - Syapse; Syapse; Syapse; Syapse
 
Wesley Allan Papenfuss
Consulting or Advisory Role - Intuitive Surgical; Intuitive Surgical; Intuitive Surgical; Intuitive Surgical
 
Aaron Chevinsky
Honoraria - Genomic Health; Genomic Health; Genomic Health; Genomic Health
Speakers' Bureau - Genomic Health; Genomic Health; Genomic Health; Genomic Health
 
Antony Ruggeri
Consulting or Advisory Role - Via Oncology; Via Oncology; Via Oncology; Via Oncology
 
Michael A. Thompson
Stock and Other Ownership Interests - Doximity; Doximity; Doximity; Doximity
Consulting or Advisory Role - Adaptive Biotechnologies; Adaptive Biotechnologies; Adaptive Biotechnologies; Adaptive Biotechnologies; AIM Specialty Health; AIM Specialty Health; AIM Specialty Health; AIM Specialty Health; Celgene; Celgene; Celgene; Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Strata Oncology; Strata Oncology; Strata Oncology; Strata Oncology; Syapse; Syapse; Syapse; Syapse; Takeda; Takeda; Takeda; Takeda; VIA Oncology; VIA Oncology; VIA Oncology; VIA Oncology
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); ARMO BioSciences (Inst); ARMO BioSciences (Inst); ARMO BioSciences (Inst); ARMO BioSciences (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Cancer Research and Biostatistics (Inst); Cancer Research and Biostatistics (Inst); Cancer Research and Biostatistics (Inst); Denovo Biopharma (Inst); Denovo Biopharma (Inst); Denovo Biopharma (Inst); Denovo Biopharma (Inst); Lynx Biosciences (Inst); Lynx Biosciences (Inst); Lynx Biosciences (Inst); Lynx Biosciences (Inst); PrECOG (Inst); PrECOG (Inst); PrECOG (Inst); PrECOG (Inst); Strata Oncology (Inst); Strata Oncology (Inst); Strata Oncology (Inst); Strata Oncology (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle); UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle); UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle); UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle)
Travel, Accommodations, Expenses - GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Syapse; Syapse; Syapse; Syapse; Takeda; Takeda; Takeda; Takeda
Other Relationship - Doximity; Doximity; Doximity; Doximity